Levothyroxine Dose Management in Elderly Patients

Overtreatment Definition and Recommended TSH Targets

The French Endocrine Society recommends keeping serum TSH > 1.0 mIU/L in all patients on levothyroxine to prevent iatrogenic thyrotoxicosis; observational studies show overtreatment in 20–50 % of elderly patients and link it to serious cardiac and skeletal complications. 1, 2
For individuals aged 70–79 years, the age‑adjusted upper limit of normal TSH is 7.0 mIU/L; treatment goals should maintain TSH within this age‑specific range and never below 1.0 mIU/L. 1, 2, 3
A serum TSH of 0.23 mIU/L indicates biochemical hyperthyroidism and overtreatment, requiring dose correction to reduce morbidity and mortality risk. 2, 3

Overtreatment with levothyroxine markedly increases the risk of atrial fibrillation in elderly patients, a life‑threatening condition that can lead to stroke and heart failure. 2, 3
Approximately 20 % of levothyroxine‑treated patients are overtreated; large population studies associate this overtreatment with increased cardiovascular mortality. 2, 3
Suppressed TSH accelerates bone loss in post‑menopausal women, raising fracture risk in older adults. 2, 3

Re‑measure serum TSH 6–8 weeks after a dose change to allow the new steady‑state concentration to be reached. 1, 2, 3
The target TSH for an elderly patient should be 1.0–7.0 mIU/L, keeping the lower bound above 1.0 mIU/L to avoid thyrotoxicosis while respecting the age‑appropriate upper limit. 1, 2, 3
Once TSH is stabilized within the 1.0–7.0 mIU/L range, annual TSH testing is sufficient if the clinical condition remains unchanged. 1, 2, 3
If TSH remains suppressed after the initial reduction, further 12.5 µg decrements should be made, with repeat TSH testing every 6–8 weeks until the target range is achieved. 1

Do not rely on the patient’s subjective feeling of well‑being to justify maintaining a low TSH; subclinical hyperthyroidism still carries significant cardiovascular and skeletal risks over time. 2, 3
Do not apply the TSH targets used for younger adults to elderly patients; age‑specific targets are essential to prevent both under‑ and overtreatment. 1, 2, 3